Clinical trials
Hypercholesterolemia trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 18 |
| Sanofi | 8 |
| Novartis Pharmaceuticals | 5 |
| Kastle Therapeutics, LLC | 2 |
| Merck Sharp & Dohme LLC | 2 |
| NewAmsterdam Pharma | 2 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2 |
| Takeda | 2 |
| The Medicines Company | 2 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypercholesterolemia | 48 |
| Dyslipidemias | 10 |
| Hyperlipidemias | 9 |
| Hyperlipoproteinemia Type II | 8 |
| Homozygous Familial Hypercholesterolemia | 4 |
| Cardiovascular Diseases | 3 |
| Atherosclerosis | 2 |
| Coronary Artery Disease | 2 |
| Angina Pectoris | 1 |
| Aortic Valve Stenosis | 1 |
Trials
Showing 51 to 48 of 48. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.